Biomarkers That Predict Response to High-Dose Aldesleukin in Metastatic Kidney Cancer or Metastatic Melanoma

CompletedOBSERVATIONAL
Enrollment

15

Participants

Timeline

Start Date

October 2, 2007

Primary Completion Date

February 18, 2009

Study Completion Date

April 16, 2010

Conditions
Kidney CancerMelanoma (Skin)
Interventions
BIOLOGICAL

aldesleukin

GENETIC

gene expression analysis

GENETIC

mutation analysis

OTHER

flow cytometry

Trial Locations (1)

68198-6805

University of Nebraska Medical Center, Eppley Cancer Center, Omaha

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Nebraska

OTHER

NCT00617799 - Biomarkers That Predict Response to High-Dose Aldesleukin in Metastatic Kidney Cancer or Metastatic Melanoma | Biotech Hunter | Biotech Hunter